Decree of the Rector n. 1231 of 28/11/2023
Competition for awarding 1 research grant at the University of Udine

DISCLAIMER:
The official and legally binding call for applications is in Italian only.
This document cannot be used for legal purposes and is only meant to provide information in English on the call for applications (Decree of the Rector n. 1231 of 28/11/2023). Please refer to the official call published on: https://www.uniud.it/it/albo-ufficiale

Any change and integration will be made available on the above mentioned web page. Therefore, no personal written communication regarding the examination date and/or competition results shall be provided to applicants.

Annex 1

Competition announcement for the assignment of 1 research grant at the University of Udine, entitled “Identification of Clonal Hemopoiesis and secondary myeloid neoplasia risk assessment in patients infused by Chimeric Antigen Receptor T (CAR-T) cells” SSD: MED/15 (principal investigator, Eleonora Toffoletti)

Research grant funded by the resources of the project PRIN 2022 - Prot. n. 20227RLEL8

Art. 1
A selection procedure is hereby launched for the award of 1 research grant at the University of Udine, as identified in Attachment A which constitutes an integral part of the present announcement. The research grant is linked to the research project and is subject and conditioned upon the relative funding. The fellowship may be renewed, in compliance with Art. 22, Law No. 240 of 30 December 2010 (as in the text in force before the implementation of the Conversion Law of the D.L. 36/2022, L. 79/2022), Law No. 11 of 27 February 2015, and the current regulations of the University of Udine for awarding research grants, issued with the Rector’s Decree No. 182 of 31 March 2021. The renewal is subject to the scientific coordinator’s positive assessment of the researcher’s activities, an adequate scientific rationale, and a corresponding financial covering.

The research fellowship does not give rise to any right with regards to accessing University posts.

Any personal communication to candidates related to this selection will be sent exclusively to the email address indicated when registering for the selection, as mentioned in Art. 5.

Art. 2
The research grant described in this competition announcement and the required qualifications to apply for the position are identified in Attachment A. The lack of the admission requirements leads to the automatic exclusion from the competition procedure.

Possession of a PhD or equivalent degree obtained abroad or, only for the interested areas, of a medical specialization accompanied by an adequate scientific production, constitutes a preferential
qualification for awarding the research fellowship of this selection, if it has not been provided as a mandatory requirement.

Candidates in possession of a specialization qualification in the medical area obtained abroad must also attach the recognition decrees issued by the Italian Ministry of Health in order to avail themselves of the qualification of specialist doctor and of the title of surgeon. These recognition decrees are also required if the qualification has already been recognized in another country of the European Union. http://www.salute.gov.it/ProfessioniSanitariePubblico/

For the only purpose of the admission to the competition, the Examining Board (Art. 7) shall assess the equivalence of the qualification obtained abroad, except for the evaluation of the medical specialization qualification to which Article 38 of the Legislative Decree 165/2001 and subsequent modifications and additions, and EU regulations on the matter, shall be applied.

The Examining Board will proceed to the evaluation of the qualification obtained abroad according to the documentation attached to the application form. The Examining Board may exclude the candidate if the submitted documentation does not provide sufficient information for the assessment. Therefore, applicants must enclose all the documentation in their possession relating to their qualification in order to provide the Examining Board with sufficient information for assessment.

Candidates holding a qualification issued by a European Research Area country, if successful, must submit, if not already attached to the application form one of the following options:
- Supplement Diploma in English issued by the competent University.
- CIMEA Certificate of comparability of the foreign qualification, issued by CIMEA (Information Centre on Academic Mobility and Equivalence) via the "diplome" service at https://cimea.dipломa.eu/udine/#/auth/login

Candidates holding a qualification issued by a non-European Research Area country, if successful, must submit, if not already attached to the application form one of the following options:
- Declaration of the on-site value of the qualification and the certificate relating to the degree with examinations and grades. A certificate in a language other than Italian or English must be accompanied by an official translation into one of these languages (certified by the competent diplomatic-consular authority or certified by a court in Italy).
- CIMEA Certificate of comparability of the foreign qualification, issued by CIMEA (Information Centre on Academic Mobility and Equivalence) via the "diplome" service at https://cimea.dipлома.eu/udine/#/auth/login

If the Supplement Diploma or the statement/attestation of comparability are not available when signing the contract, the applicant must demonstrate that he/she has requested the documentation and submit it as soon as possible.

Any exclusion from the selection procedure due to lack of eligibility requirements, absence of required documents, failure to sign the selection application or submission of the selection application in a manner different from what is provided for in this call for applications will be communicated to applicants exclusively at the email address indicated in the application form.
Art. 3
The research grant referred to in this call for applications cannot be awarded:

a. to employees of Universities and the entities referred to in Article 22, section 1, of Italian Law no. 240 of 30 December 2010 (in the text prior to the reform introduced by Law no. 79 of 29 June 2022);
b. to those who have already been awarded research grants pursuant to Italian Law no. 240 of 30 December 2010 (prior to the reform introduced by Law no. 79 of 29 June 2022) for the maximum period provided by law, even if not continuously, excluding the period in which the grant was used in conjunction with the doctorate, up to the legal term of the relative course;
c. to those who have already benefited from research grants and fixed-term researcher contracts provided for, respectively, in Articles 22 and 24 of Italian Law no. 240 of 30 December 2010 (in the text prior to the reform introduced by Law no. 79 of 29 June 2022), for a total of 12 years, even if not consecutive;
d. to anyone who has a degree of kinship or affinity, up to and including the fourth degree, with:
   - the Rector, the Director General or a member of the Board of Directors of the University of Udine;
   - the scientific supervisor or a professor/researcher belonging to the department or organisation hosting the research grant in question.

The research grant provided for in this call for applications cannot be combined:

a) with scholarships of any kind, except for those granted by Italian or foreign institutions to supplement, by means of stays abroad, the fellow's training or research activities;
b) with other research grants;
c) with an employment relationship, even if part-time, without prejudice to the relevant provisions for employees of public administrations.

The grant awarded under this call for applications is also incompatible with simultaneous attendance at university degree courses, either Bachelor's degree or Master’s degree courses, research Doctorates with scholarships and medical specializations, in Italy or abroad.

Art. 4
Applicants must enclose with their application, under penalty of exclusion, the following documents:

a) their professional scientific CV, highlighting the candidate's aptitude for carrying out and implementing the research project (Attachment A);
b) their identity card, their passport or any other identification document⁴;
c) (for candidates with a foreign qualification only) certification or self-certification of both the academic qualification required for the admission to the selection, and of the exams (with evaluation) took during the period of study abroad, and of any other document that can be useful to the evaluation of the degree by the Examining Board.

Applicants can attach to the application, publications and any other certification considered useful to demonstrate the qualification based on the research program (Attachment A) and to certify any research activity accomplished at public or private institutes (indicating the starting and ending date and the duration).

The documents and qualifications mentioned above must be submitted in Italian or English. Those that are not as requested will not be evaluated. Documents originally written in a language other than

---

⁴ Please be aware that the residence permit is not an identification document.
Italian or English must come with a translation in Italian or English, that the candidate will do on its own responsibility. The translation can be an abstract concerning the thesis.

Italian and Community candidates wishing to submit qualifications referring to conditions and facts attested by Public Administrations must proceed exclusively with self-certification. Non-EU citizens legally residing in Italy may self-certify only data that can be verified or certified by Italian public bodies. They may also use declarations in lieu when provided for by an international convention between Italy and the declarant's country of origin.

Non-EU citizens not residing in Italy cannot self-certify.

Only the qualifications possessed by the candidate on the date the application form is submitted and submitted in accordance with the procedures set out in Article 5 will be assessed.

Failure to submit mandatory documents provided for in this article will constitute grounds for exclusion from the selection.

Art. 5

The submission of the applications for the present call starts on December 7, 2023 at 2:00 pm (Italian time) and ends on January 12, 2024 at 2:00 pm (Italian time).

The application to take part in the selection must be completed, under penalty of exclusion, using the appropriate online procedure, available at the link https://pica.cineca.it/

The procedure involves an applicant registration step, for those who do not already have an account, and then an application completion step.

Once completed, the online application must be signed in the manner described in the online procedure (manual signature with attached identity document or digital signature), under penalty of exclusion from selection. The application does not have to be signed if you access the above-mentioned online procedure using your SPID ID.

The qualifications referred to in Article 4 must be attached to the application in .pdf format. Individual .pdf files may not exceed 30MB.

The application for participation in the selection is automatically sent to the University of Udine with the definitive closing of the online procedure.

The University Administration:
- is not responsible if it is impossible to read the submitted documentation in electronic format due to damaged files;
- shall not accept or take into consideration qualifications or documents received in paper form or by any means other than what is specified in this article.

Reference to documents or publications already submitted in connection with other competitions is not allowed.

The Administration is not responsible for any missing document or communication because of inaccurate indication of residence and/or address submitted by the candidate during the application. Also, the Administration is not responsible if the candidate has not communicated changes in this information, or has communicated them too late. The Administration is also not responsible for any postal or telegraphic problems not attributable to the Administration itself.
Applicants are advised not to wait until the last few days before the closing date to submit their application. The University accepts no responsibility for any malfunctions due to technical problems and/or overloading of the communication line and/or application systems.

**Art. 6**
The selection procedure is held in accordance with the modality indicated in Attachment A.

The test will aim to assess the general preparation, experience and aptitude for research of the candidate. It will consist in the evaluation of the professional scientific curriculum, of the publications and qualifications presented, and of the interview, where foreseen.

**Art. 7**
The Examining board for the competition is identified in Attachment A of the present competition announcement, of which it is an integral part.

At its first meeting, the Examining board shall appoint its President and Secretary, and establish the criteria and methods for evaluating the qualifications and the interview, where foreseen.

The results of the qualifications assessment must be disclosed to applicants during the interview, where foreseen.

The Examining board can award a maximum of 100 points (one hundred out of one hundred) to the selection.

At the end of the evaluation procedure, the Examining board shall formulate the general merit list based on the overall score of each candidate, and draw up the minutes of the whole competition procedure.

Based on the ranking list, the assignment is awarded to candidates who have obtained a minimum overall score of 70/100 (seventy out of one hundred).

The Examining board's judgement is final.

The ranking list will be made public exclusively through publication on the University's official website.

Applicants will not be notified of the outcome of the evaluation.

Those who do not declare their acceptance of the research grant and do not present themselves at the research centre within the deadline communicated by the latter, even if not formally, shall lose the right to receive it. Exceptions to this term will only be granted in cases of documented force majeure.

The selected candidate will have to undergo any health assessment deemed necessary by the competent doctor and aimed at issuing the assessment of suitability for the specific task according to the protocol of the host structure. The signature of the contract will be possible only after obtaining the judgment of suitability for the specific task by the Azienda Sanitaria Universitaria Friuli Centrale (ASU FC). Before signature of the research grant contract, the candidate awarded of reference research grant must submit a copy of the vaccination booklet or related certificate, and intradermal reaction – sec. Mantoux (performed in the last 12 months).
Art. 8

The research activity cannot be started before signing the contract defining the terms and conditions of the collaboration.

The activity covered by the research grant must have the following characteristics:

a) it must be carried out as part of the research programme covered by the grant and not be a merely technical support to it;

b) it must have a close connection with the realization of the research program for which the winner of the grant has been awarded the contract;

c) it must be continuous and, in any case, temporally defined, not merely occasional, and in coordination with the overall activity of the University;

d) it must be carried out autonomously, solely within the limits of the programme prepared by the programme supervisor, without predetermined working hours.

The researcher is required to submit a detailed written report on the work carried out and the results achieved, accompanied by the opinion of the scientific supervisor, to the reference organisation at the intervals set out in the contract. The researcher must also submit interim reports and timesheets, if requested by the reference organisation.

Either the fellow or the reference organisation may withdraw from the contract. The reference organisation may terminate the contract not only in the cases referred to in Article 9, sections 2 and 3, of the "Internal rules for awarding research grants pursuant to law 240 of 30 December 2010" of the University of Udine, but also in the event the research project and therefore the financial coverage on which the research grant is based cease to exist.

With regard to accident insurance and third-party liability, the provisions of art. 3 c. 5 of the "Internal rules for awarding research grants pursuant to Italian Law no. 240 of 30 December 2010" of the University of Udine, issued by Rector's Decree no. 182 of 31 March 2021, are applied. The Azienda Sanitaria Universitaria Friuli Centrale (ASU FC), by authorizing with a subsequent deed the access of the selected candidate to its facilities, ensures insurance cover for professional risks and third-party liability in the course of the authorized activity. The insurance policy for accidents and occupational diseases remains at the expense of the selected candidate. In the absence of such policy, the selected candidate will not be allowed to access the facilities of the Azienda Sanitaria Universitaria Friuli Centrale (ASU FC), and it will not be possible to proceed with the signature of the contract.

Art. 9

The following legal dispositions shall apply to the grant referred to in this call for applications:

- for tax matters, the provisions of Article 4 of Italian Law no. 476 of 13 August 1984, as subsequently amended and supplemented;

- for social security matters, the provisions of Article 2(26) et seq. of Italian Law no. 335 of 8 August 1995, as subsequently amended and supplemented;

- for mandatory maternity leave, the provisions of the Italian Ministerial Decree of 12 July 2007;

- with regard to sick leave, the provisions of Article 1(788) of Italian Law no. 296 of 27 December 2006 and subsequent amendments.
During the period of mandatory maternity leave, the allowance paid by INPS according to Art. 5 of the Italian Ministerial Decree of 12 July 2007 is supplemented by the University up to the full amount of the research grant.

The grant will be paid in monthly instalments.

**Art. 10**

The data collected as part of the procedure referred to in Art. 5 are necessary to properly manage the selection procedure, for any subsequent management of the research grant and for purposes related to managing services provided by the University. The University of Udine is the Data Controller. At any time, the data subject may request access, rectification and, depending on the University’s institutional purposes, cancellation and restriction of processing or oppose the processing of their data. The data subject can always lodge a complaint with the Italian Data Protection Authority. The complete disclosure is available on the University of Udine website in the “Privacy” section, accessible from the home page [www.uniud.it](http://www.uniud.it) Direct Link: [https://www.uniud.it/it/pagine-speciali/guida/privacy](https://www.uniud.it/it/pagine-speciali/guida/privacy)

**Art. 11**

For all matters not expressly mentioned in this call for applications, refer to the regulations in force on the subject cited in the introduction and to the "Internal rules for awarding research grants pursuant to Italian Law no. 240 of 30 December 2010" of the University of Udine, issued by Rector's Decree no. 182 of 31 March 2021.

**Art. 12**

The procedure supervisor is Dr Sandra Salvador, Head of the Research Services Area of the University of Udine.

The Responsible office at the University of Udine is "Area Servizi per la Ricerca - Ufficio Formazione per la Ricerca", via Mantica n. 31 - 33100 Udine, Italia.

To request information about the call for applications, please complete the following form available on the University of Udine website: [https://helpdesk.uniud.it/SubmitSR.jsp?type=req&accountId=universityofudine&populateSR_id=42105](https://helpdesk.uniud.it/SubmitSR.jsp?type=req&accountId=universityofudine&populateSR_id=42105)
Responsabile scientifico della ricerca / Principal investigator:

Nome e cognome / Name and surname: Eleonora Toffoletti
Qualifica / Position: Ricercatrice Universitaria / Researcher
Dipartimento / Department: Area Medica / Medicine
Area MUR / Research field: 06 - Scienze Mediche / Medical Sciences
Settore concorsuale e Settore scientifico disciplinare / Scientific sector: 06/D3; MED/15 - Malattie del sangue

Titolo dell’assegno di ricerca / Topic of the research fellowship “assegno di ricerca”:
I bandi sono consultabili dal sito dell’Ateneo, del MUR e di Euraxess / The calls are available on the University, MUR and Euraxess websites

Testo in italiano:
Identificazione dell’emopoiesi clonale e valutazione del rischio evolutivo a neoplasia mieloide secondaria in pazienti trattati con cellule T con recettore antigenico chimerico (CAR-T).

Text in English:
Identification of Clonal Hemopoiesis and secondary myeloid neoplasia risk assessment in patients infused by Chimeric Antigen Receptor T (CAR-T) cells.

Obiettivi previsti e risultati attesi del programma di ricerca in cui si colloca l’attività dell’assegnista di ricerca / Foreseen objectives and results of the research programme performed by the research fellow “assegno di ricerca”:
I bandi sono consultabili dal sito dell’Ateneo, del MUR e di Euraxess / The calls are available on the University, MUR and Euraxess websites

Testo in italiano:
La terapia con cellule T con recettore antigenico chimerico (chimeric antigen receptor T cells o CAR-T cells) rappresenta un approccio terapeutico rivoluzionario che ha mostrato incredibili risultati in alcuni linfomi B refrattari alle terapie convenzionali: gli studi JULIET e ZUMA-1 riportano delle risposte a lungo termine nel 30-40% dei casi di Linfoma B Diffuso a Grandi Cellule (DLBCL) ricaduti e/o refrattari. Tale dato rappresenta un miglioramento eccezionale rispetto allo storico 7% di lungo sopravvivenso ottenuto su analoga popolazione di pazienti nel trial SCHOLAR-1. Tuttavia, oltre a questi risultati eccezionali, sono emerse anche delle tossicità acute e tardive. Tra gli effetti avversi tardivi, le citopenie rappresentano una complicazione frequente e poco prevedibile. Dopo l’infusione di cellule CAR-T, la citopenia può presentarsi come effetto della terapia linfopenizzante eseguita pre-infusione, ma, in circa la metà dei casi trattati, si presenta in forma severa dopo i primi 30 giorni dall’infusione, esponendo il paziente a infezioni da opportunisti e sindrome emorragica, oltre che a complicare la gestione del paziente. Questo fenomeno non è ancora stato ben studiato e i fattori di rischio sembrano essere la numerosità delle terapie precedenti, l’età, la scarsa cellularità midollare residua, la severità della sindrome da rilascio citochinico, l’entità della malattia ematologica presente al momento dell’infusione di cellule CAR-T e la presenza di Emopoiesi Clonale di Potenziale Indeterminato (Clonal Hemopoesis of Indeterminate Potential o CHIP). La presenza di CHIP pre-infusione è stata identificata in circa il 32-48% dei pazienti sottoposti a cellule CAR-T, ma risulta associata ad un miglior tasso di risposte complete e una miglior sopravvivenza globale. Le neoplasie mieloide legate a terapia (t-MNs) sono delle neoplasie secondarie che si sviluppano come complicanza tardiva ad una terapia citotossica e non sono geneticamente correlate alla neoplasia precedente. Tali neoplasie vengono osservate nei soggetti trattati con terapia citotossica e autotrasplantato e tra i fattori di rischio di t-MN si registra anche la presenza di CHIP pre terapia citotossica nel sangue periferico, anche se presente a bassa Variant Allelic Fraction (VAF). Il
meccanismo per cui la presenza di CHIP influenza l’outcome della terapia con cellule CAR-T non è noto, anche perché la presenza di CHIP non è mai stata valutata post reinflusione in soggetti trattati con cellule CAR-T nel sangue perifero intero o in sottopopolazioni cellulari selezionate. In conclusione, molti elementi suggeriscono una interconnessione complessa tra CHIP, funzione T cellulare e insorgenza di neoplasie mieloidi secondarie. Lo studio di questi aspetti e la comprensione della loro interazione potrebbe rivelarsi estremamente importante per il paziente sottoposto a cellule CAR-T, sia per il miglioramento della loro efficacia che per la gestione degli effetti avversi a medio (citopenie) e a lungo termine (neoplasie mieloidi secondarie).

Obiettivi del progetto
- Obiettivo primario: identificazione dell'ematopoiesi clonale (CHIP) e di eventuali lesioni molecolari preleucemiche nel comparto mieloide e nei linfociti CD3+ di pazienti con Patologie Linfoidi Maligne ricaduti/refrattari che sono stati candidati a cellule CAR-T.
- Obiettivo secondario: identificare possibili correlazioni tra la presenza di CHIP mieloide e/o linfoide con l'insorgenza di citopenie prolungate dopo CAR-T ed eventuali neoplasie mieloidi secondarie.

Descrizione del progetto
Il materiale biologico prelevato in precise finestre temporali dovrà essere manipolato e conservato adeguatamente. L’assetto mutazionale verrà studiato sul DNA isolato da sangue midollare intero, sangue perifero intero e linfociti CD3+ selezionati. Verranno effettuate analisi in Next Generation Sequencing su piattaforma Illumina con pannello mieloide alla ricerca di mutazioni a carico dei geni toxiche, identificando le varianti di nuova identificazione.

Metodi previsti
- manipolazioni di biologia cellulare;
- metodiche di biologia molecolare tradizionale;
- next generation sequencing su piattaforma Illumina MiSeq;
- analisi statistiche.

Text in English:
Chimeric Antigen Receptor T-cells (CAR-T cells) therapy is a revolutionary biologic drug that has already shown tremendous improvement in the outcome of some refractory B-cell malignancies: the JULIET and ZUMA-1 trials reported long-term responses in 30-40% of relapsed-refractory (r/r) Diffuse Large B Cell Lymphoma (DLBCL), representing a notable progress over the historical mark of 7% of long-term survivors in the SCHOLAR-1 study.

However, such remarkable efficacy is obtained at cost of some acute and later toxicities. Among later toxicities, cytopenias represent a frequent and poorly understood complication. Cytopenias after CAR-T cells may present early as a result of lymphodepletive therapy but occurs in a severe form in up to half of cases after the first 30 days from infusion, thus putting at risk of opportunistic infections or bleeding and causing implications for patient care and resource utilization. Moreover, this phenomenon is poorly understood: risk factors include the burden of previous treatment, age, poor bone-marrow, severity of CRS, the extent of the hematologic disease at infusion, and the finding of clonal hematopoiesis of indeterminate potential (CHIP).

CHIP has been evaluated in patients receiving CAR-T cells and was found in 32 – 48% of cases; of note, CHIP was not associated with worse prognosis but with improved rates of complete response or better overall survival.

Therapy-related Myeloid Neoplasms (t-MNs) are secondary malignancies that occur as late complication of cytotoxic therapy and are not correlated to prior neoplasm. The presence of CHIP in peripheral blood, even if at low Variant Allelic Fraction (VAF), before any cytotoxic therapy increase the t-MN risk. The mechanisms by which CHIP influence CAR-T efficacy remain to be elucidated, because
CHIP was never evaluated after CAR-T infusion in whole peripheral blood nor in fractionated blood populations.

In conclusion, several clues suggest a complex interplay between CHIP, T-cell function and emergence of myeloid neoplasms. Understanding these interactions can be of critical importance in the patient receiving CAR-T cells, given the consequences on the efficacy of CAR-T cells and their potential adverse effects in the medium (cytopenias) or long term (secondary myeloid neoplasms).

Objectives of the project
- Primary objective: Identification of Clonal Hematopoiesis (CHIP) and pre-leukemic abnormalities not only in myeloid compartment but also in CD3+ lymphocytes in patients with relapsed-refractory Lymphoid Malignancies receiving Chimeric Antigen Receptor (CAR) T cells.
- Secondary objectives: correlation between myeloid and lymphoid CHIP and prolonged cytopenias after CAR-T cells infusion and secondary Myeloid Neoplasia.

Project description
Biological samples collected at specific time point will be manipulated and conserved adequately. The molecular abnormalities will be studied on DNA isolated by whole bone marrow (BM) samples, by whole peripheral blood (PB) and by selected peripheral T CD3+ lymphocytes. CHIP will be investigated before and after CAR-T cells infusion thanks to a Next Generation Sequencing panel-based approach, pointing to myelopoiesis involved genes. WT1 expression analysis, as prognostic marker of leukemic transformation, and single variant confirmation will be carried out thanks to traditional molecular approaches. Clinical and biological data will be collected and analysed by statistical softwares.

Planned methods
- cellular biology;
- traditional molecular biology (gene expression analyses, sanger sequencing);
- next generation sequencing on Illumina MiSeq platform
- statistical analyses.

Struttura dell’Università di Udine presso la quale verrà sviluppata l’attività di ricerca / Department or other structure of the University of Udine where research activities will be carried out:

Dipartimento di Area Medica / Department of Medicine

Tipologia di attività assistenziale prevista in relazione alle esigenze del programma di ricerca / Type of care activity scheduled in relation to the needs of the research program:
- Nessun contatto con pazienti ma solo con dati clinici sensibili. / No contact with patients but only with sensitive clinical data.
- Attività di laboratorio diagnostico senza finalità assistenziale. / Diagnostic laboratory activity without assistance purposes.

Struttura ospedaliera coinvolta / Hospital facility involved:

Azienda Sanitaria Universitaria Friuli Centrale (ASU FC), Presidio Ospedaliero Universitario Santa Maria della Misericordia – Udine, SOC Clinica Ematologica.
Importo dell’assegno di ricerca (al lordo oneri carico assegnista) / Total grant gross for the research fellowship:

€ 32.428,80

Durata dell’assegno di ricerca / Duration of the research fellowship “assegno di ricerca”:

20 mesi / months

Finanziamento / Financed by:


Requisiti di ammissione / Minimum qualifications necessary:

- Possesso di un diploma di laurea vecchio ordinamento (ante decreto 3 novembre 1999 n. 509) o di laurea specialistica/magistrale (ex decreto 3 novembre 1999 n. 509 e decreto 22 ottobre 2004 n. 270) o titolo equivalente conseguito all’estero;
- possesso di un curriculum scientifico professionale idoneo allo svolgimento dell’attività di ricerca contemplata.
- University degree obtained before Decree n. 509 of 3 November 1999 or specialistic/Master’s degree (post decree n. 509 of 3 November 1999 and decree n. 270 of 22 October 2004) or equivalent degree obtained abroad;
- professional scientific curriculum suitable for the research activity above mentioned.

Procedura selettiva / Competition procedure:

Valutazione per titoli e colloquio / Evaluation of titles and oral exam

I risultati della valutazione dei titoli saranno resi noti agli interessati nel corso del colloquio / The evaluation of the qualifications will be disclosed to candidates during the interview

<table>
<thead>
<tr>
<th>Calendario del colloquio / Calendar of the oral exam</th>
<th>Modalità / Modality</th>
<th>Videoconferenza / Videoconference</th>
</tr>
</thead>
<tbody>
<tr>
<td>Data / Date</td>
<td>22 gennaio / January 2024</td>
<td></td>
</tr>
<tr>
<td>Ora / Time</td>
<td>14:30 / 2:30 pm (Italian time)</td>
<td></td>
</tr>
<tr>
<td>Luogo / Place</td>
<td>-</td>
<td></td>
</tr>
</tbody>
</table>

Per sostenere il colloquio i candidati devono esibire un valido documento di riconoscimento. / Candidates must come to the interview with a valid identity document.

Eventuali variazioni saranno rese note esclusivamente mediante pubblicazione all’albo ufficiale on line dell’Ateneo / Any change will be made public solely through publication on the University web site [http://web.uniud.it/ateneo/normativa/albo_ufficiale](http://web.uniud.it/ateneo/normativa/albo_ufficiale)
Nota / Note: Le indicazioni sulle modalità di svolgimento della prova in modalità telematica saranno inviate ai candidati con successiva email da parte del Presidente della Commissione. Ai fini dell’identificazione e a pena di esclusione dalla procedura selettiva, ciascun candidato è tenuto ad identificarsi prima che il colloquio abbia inizio, esibendo il medesimo documento di identità allegato alla domanda di ammissione al concorso. Il candidato deve risultare reperibile nella giornata e all’orario indicato sul bando. Il mancato collegamento, l’irreperibilità del candidato nel giorno o nell’orario stabilito o la mancata esibizione del documento identificativo, sono motivo di esclusione dalla procedura selettiva. La registrazione delle prove orali è vietata. L’Ateneo adotterà pertanto tutti i provvedimenti in suo potere per tutelare i soggetti coinvolti qualora venissero diffuse tramite internet – o altri mezzi di diffusione pubblica – video, audio o immagini della procedura selettiva. / Instructions on how the video interviewing will be conducted will be provided to candidates by the Chairman of the Examining Board via email. For identification purposes, each candidate is required to identify him/herself before the interview by exhibiting the same identification document attached to the application. Candidates must be available on the day and time established by the call for applications. Failure of the candidate to establish a video connection, the unavailability of the candidate on the day and/or time established or failure of the candidate to provide the required identification document are all grounds for exclusion from the selection procedure. Recording of the video interviews is prohibited. The University will adopt all the measures within its power to protect all personnel involved as a result of dissemination via the internet or via other forms of public dissemination, of videos, audios or other pictures of the selection procedures.

Commissione giudicatrice / Examining Board:

<table>
<thead>
<tr>
<th>Nome e Cognome / Name</th>
<th>Qualifica / Qualification</th>
<th>SSD / SSD</th>
<th>Università / University</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Membri Effettivi / Permanent members</strong></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Gianluca Tell</td>
<td>PO</td>
<td>BIO/11</td>
<td>Università degli Studi di Udine</td>
</tr>
<tr>
<td>Francesca Patriarca</td>
<td>PA</td>
<td>MED/15</td>
<td>Università degli Studi di Udine</td>
</tr>
<tr>
<td>Mario Tiribelli</td>
<td>RU</td>
<td>MED/15</td>
<td>Università degli Studi di Udine</td>
</tr>
<tr>
<td><strong>Membro Supplente / Temporary member</strong></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Giulia Antoniali</td>
<td>PA</td>
<td>BIO/11</td>
<td>Università degli Studi di Udine</td>
</tr>
</tbody>
</table>